A new phase III clinical trial called COMPETE (NCT03049189 ) compares everolimus, an oral targeted
diagnosis, treatment, research
You can Spark Hope for a brighter future. Make a gift. Host an event. Or volunteer to help us advance our understanding of neuroendocrine tumors.
Join Our Mailing List
Learn about neuroendocrine tumor tests, treatments, and research. Find out about educational and inspirational events in the NET community.